Daiichi Sankyo Company, Limited (D4S.F)
- Previous Close
28.40 - Open
29.27 - Bid 28.13 x 50000
- Ask 28.97 x 50000
- Day's Range
29.27 - 29.27 - 52 Week Range
22.35 - 34.48 - Volume
135 - Avg. Volume
170 - Market Cap (intraday)
56.418B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
49.61 - EPS (TTM)
0.59 - Earnings Date --
- Forward Dividend & Yield 0.37 (1.29%)
- Ex-Dividend Date Mar 28, 2024
- 1y Target Est
--
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
www.daiichisankyo.com17,435
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: D4S.F
Performance Overview: D4S.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: D4S.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: D4S.F
Valuation Measures
Market Cap
54.74B
Enterprise Value
48.18B
Trailing P/E
48.51
Forward P/E
46.30
PEG Ratio (5yr expected)
1.48
Price/Sales (ttm)
6.00
Price/Book (mrq)
5.69
Enterprise Value/Revenue
0.03
Enterprise Value/EBITDA
0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
12.38%
Return on Assets (ttm)
3.73%
Return on Equity (ttm)
12.43%
Revenue (ttm)
1.5T
Net Income Avi to Common (ttm)
186.05B
Diluted EPS (ttm)
0.59
Balance Sheet and Cash Flow
Total Cash (mrq)
1.2T
Total Debt/Equity (mrq)
6.41%
Levered Free Cash Flow (ttm)
-22.62B
Research Analysis: D4S.F
Company Insights: D4S.F
D4S.F does not have Company Insights